Overview

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis.

Phase:

PHASE2

Details

Lead Sponsor:

Convalife (Shanghai) Co., Ltd.

Treatments:

Capecitabine
neratinib